Epirus Biopharmaceuticals
As of the edition of 20 October 2026, Epirus Biopharmaceuticals runs 4 drugs; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
- Zalicus: dissolved
Drugs by status
| Status | Count |
|---|---|
| Went quiet | 4 |
| Total | 4 |
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| CACNA1B Voltage-dependent N-type calcium channel subunit alpha-1B | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Epirus Biopharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Skin and connective tissue: 2 trials led
- Bones, joints and muscles: 1 trials led
- Hormones: 1 trials led